Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: 6MHP
DRUG: Montanide ISA-51
DRUG: polyICLC
DRUG: CDX-1127

Sponsor

Craig L Slingluff, Jr

Collaborators

[object Object]